S11 Ep3: FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

from OncLive® On Air · host OncLive® On Air

Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.

Episode metadata supplied by the publisher feed · Published Aug 15, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

S11 Ep3: FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

0:00 9:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 9 minutes long.

This episode was published on August 15, 2024.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!